tetano
Editor, Senior Moderator
J Med Chem. 2018 Jan 17. doi: 10.1021/acs.jmedchem.7b01536. [Epub ahead of print]
[h=1]In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.[/h] Wang Y[SUP]1[/SUP], Hu Y[SUP]1[/SUP], Xu S[SUP]1[/SUP], Zhang Y[SUP]1[/SUP], Musharrafieh R[SUP]2[/SUP], Hau RK[SUP]1[/SUP], Ma C[SUP]3[/SUP], Wang J[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses are respiratory pathogens that are responsible for both seasonal influenza epidemics and occasional influenza pandemics. The narrow therapeutic window of oseltamivir, coupled with the emergence of drug resistance, calls for the next-generation of antivirals. With our continuous interest in developing AM2-S31N inhibitors as oral influenza antivirals, we report here the progress of optimizing the in vitro pharmacokinetic (PK) properties of AM2-S31N inhibitors. Several AM2-S31N inhibitors, including compound 10b, were discovered to have potent channel blockage, single to submicromolar antiviral activity, and favorable in vitro PK properties. The antiviral efficacy of compound 10b was also synergistic with oseltamivir carboxylate. Interestingly, binding kinetic studies (K[SUB]d[/SUB], K[SUB]on[/SUB], and K[SUB]off[/SUB]) revealed several AM2-S31N inhibitors that have similar K[SUB]d[/SUB] values but significantly different K[SUB]on[/SUB] and K[SUB]off[/SUB] values. Overall, this study identified a potent lead compound (10b) with improved in vitro PK properties that is suitable for the in vivo mouse model studies.
PMID: 29341607 DOI: 10.1021/acs.jmedchem.7b01536
[h=1]In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses.[/h] Wang Y[SUP]1[/SUP], Hu Y[SUP]1[/SUP], Xu S[SUP]1[/SUP], Zhang Y[SUP]1[/SUP], Musharrafieh R[SUP]2[/SUP], Hau RK[SUP]1[/SUP], Ma C[SUP]3[/SUP], Wang J[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses are respiratory pathogens that are responsible for both seasonal influenza epidemics and occasional influenza pandemics. The narrow therapeutic window of oseltamivir, coupled with the emergence of drug resistance, calls for the next-generation of antivirals. With our continuous interest in developing AM2-S31N inhibitors as oral influenza antivirals, we report here the progress of optimizing the in vitro pharmacokinetic (PK) properties of AM2-S31N inhibitors. Several AM2-S31N inhibitors, including compound 10b, were discovered to have potent channel blockage, single to submicromolar antiviral activity, and favorable in vitro PK properties. The antiviral efficacy of compound 10b was also synergistic with oseltamivir carboxylate. Interestingly, binding kinetic studies (K[SUB]d[/SUB], K[SUB]on[/SUB], and K[SUB]off[/SUB]) revealed several AM2-S31N inhibitors that have similar K[SUB]d[/SUB] values but significantly different K[SUB]on[/SUB] and K[SUB]off[/SUB] values. Overall, this study identified a potent lead compound (10b) with improved in vitro PK properties that is suitable for the in vivo mouse model studies.
PMID: 29341607 DOI: 10.1021/acs.jmedchem.7b01536